Hinge Health is considering delaying its IPO as the markets plummet on Trump tariffs
Hinge Health is considering delaying its IPO plans amid a plunging stock market.
The physical therapy startup still hopes its "recession-proof" model will still draw investor attention.
Some tech companies, including Klarna and StubHub, have reportedly already delayed their IPO plans.
Physical therapy startup Hinge Health is considering delaying its IPO as the public markets plunge in response to President Donald Trump's tariff plans, Business Insider has learned.
But the startup hopes to forge ahead with its spring IPO timeline, as a provider of critical health services.
Hinge Health filed its S-1 to go public in March and hoped to start pitching investors toward the end of April, according to a source familiar with the efforts.
After Trump announced sweeping retaliatory tariffs on Wednesday— sending the public markets into a frenzy — Hinge Health could be forced to reassess those plans.
Trump's "Liberation Day" tariffs will range from 10% to 50% on imported goods from about 90 countries, the president said Wednesday. Since that announcement, the S&P 500 has plunged more than 9%.
Hinge Health had hoped to go public sometime in April or May, keeping its plans flexible with the market volatility in mind, the person said.
That person said Hinge will still seek to IPO unless it can't draw investors' attention away from the volatility in their existing portfolios. The startup has plenty of cash on its balance sheet and doesn't need the IPO proceeds to finance the business, they said.
A representative for Hinge Health declined to comment.
Hinge isn't the only startup considering delaying its IPO plans. Payments platform Klarna and online ticket marketplace StubHub both put their plans on ice following the tariffs announcement. According to the Wall Street Journal, Klarna and StubHub planned to pitch public investors on their respective IPOs next week but decided to postpone their roadshows after the last two days of market volatility.
Klarna and StubHub both declined to comment to Business Insider.
Hinge Health would be the first healthcare delivery startup to IPO in nearly three years. The IPO market has been decidedly closed for digital health startups since 2021, and the healthcare companies from that year's IPOs haven't performed well on the public markets.
Daniel Perez and San Francisco-based company launched in 2014 to provide virtual care for joint and muscle pain. It's raised more than $1 billion from VCs, including Tiger Global, Coatue Management, Insight Partners, and Atomico, including a $400 million Series E in October 2021 at a $6.2 billion valuation.
The company's public S-1 filing in March revealed a strong financial profile for a healthcare startup. The startup reported $390 million in revenue in 2024, up 33% from the previous year's revenue, and a 77% gross margin. It's not profitable yet, but getting close, recording $45 million of free cash flow in 2024 but a net loss of $11.9 million for the full year.
The person familiar with Hinge Health's IPO plans says the startup's business is somewhat recession-proof as a healthcare benefits provider that can help drive cost savings for employers. Hinge Health also doesn't charge copays for its services, which the person said makes its platform more compelling when the costs of living surge.
Hinge Health isn't the only healthcare startup hoping for a public market debut. Omada Health confidentially filed its S-1 last summer, BI reported in October. Hinge Health rival Sword Health has also expressed interest in going public when the IPO window reopens for healthcare companies.
Jyoti Mann also contributed to this report.
Do you have a tip about Hinge Health that you want to share? Contact Rebecca Torrence (+1 423-987-0320) using the encrypted app Signal. Here are other tips on how to safely communicate with Business Insider reporters.
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Jim Cramer Says, 'Jensen Makes a Very Compelling Case When He Argues That We Should Let NVIDIA (NVDA) Sell Those Chips to the Chinese'
We recently published a list of . In this article, we are going to take a look at where NVIDIA Corporation (NASDAQ:NVDA) stands against other stocks that Jim Cramer discussed recently. A caller inquired about Cramer's thoughts on NVIDIA Corporation (NASDAQ:NVDA). Here is what he said: 'I think Jensen makes a very compelling case when he argues that we should let NVIDIA sell those chips to the Chinese because otherwise China will indeed invest much more heavily in their own semiconductor industry. Wouldn't it be better to blunt China's efforts to leapfrog us and keep them dependent on our chips, the same way we're depending on their rare earth minerals? Sadly, the White House says no. I think it makes a ton of sense.' NVIDIA (NASDAQ:NVDA) develops advanced computing, graphics, and networking solutions, offering products and software for AI, gaming, data centers, robotics, and automotive technologies. On May 13, Cramer said that President Trump's policy shift initially hurt the company, but later boosted its stock by opening up major new markets, as he said: 'As those who shorted the market now realize, the President's pivot was wildly bullish for the very companies that had previously been hit the hardest. Take NVIDIA. On the one hand, Trump effectively forced NVIDIA to take a $5.5 billion charge for chips it could no longer sell to China. On the other hand, he's now out there helping NVIDIA sell chips to some of the biggest clients in the world, the Gulf monarchies. NVIDIA stock has made a historic comeback [buy, buy, buy]… It's a big deal for the Saudis because they weren't on the arbitrary, capricious list of 18 friendly countries that President Biden approved to buy NVIDIA's best technology. Now, instead of 18 friends, we got a whole bunch of friends that can buy NVIDIA's top chips. I see many new mini hyperscale or sovereign AI countries developing.' READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio


Fox News
18 minutes ago
- Fox News
Former President Biden defends autopen use amid Republican investigation and more top headlines
1. Former President Biden defends autopen use amid Republican investigation 2. Trump signs sweeping travel ban to US targeting several high-risk countries 3. Israel recovers bodies of elderly American couple taken during Hamas attack 'OUTRAGEOUS' – Elon Musk urges Americans to 'kill' Trump's big budget bill over debt concerns. Continue reading … PARADISE LOST – Americans tourists warned of increased threat in summer vacation hotspot. Continue reading … SECRET WEAPON – Chinese-made solar panels used on American farms put US power grid at risk. Continue reading … VANTAGE POINT – Karen Read defense gets boost as key witness's account raises questions. Continue reading … TAKING A STAND – Police escort NFL player from church after demanding answers on priest porn controversy. Continue reading … -- SWITCHING SIDES – Former GOP congressman launches Democratic bid to break 30-year GOP hold on Florida governorship. Continue reading … NO BENEFITS – DOJ files suit to block red state's tuition law for illegal immigrants. Continue reading … FULL COURT PRESS – Judge throws roadblock into Trump immigration crackdown in sweeping ruling. Continue reading … ON THE LINE – Trump reveals details of hour-long call with Putin after Ukraine strike. Continue reading … JAW-DROPPING – Biden-era White House reporters express disbelief on Karine Jean-Pierre's sudden party switch. Continue reading … 'SURPRISED ME' – Dave Chappelle recalls SNL writers' tearful reaction to Trump's election victory. Continue reading … 'OUT OF CONTROL' – Former Bush official warns Putin's desperation growing after Ukraine bridge attack. Continue reading … PAVING THEIR OWN PATH – Michelle Obama says daughters pushed away from famous family to make their own success. Continue reading … HUGH HEWITT – Morning Glory: Antisemitism is shameful and evil. None of us should ever be neutral on such hate. Continue reading … SEN. JOHN CORNYN – Congress must reimburse Texas for Biden's border security malpractice. Continue reading … -- UNFAIR ADVANTAGE – Parents voice frustration as transgender girl pitcher leads team to shutout win. Continue reading … REST RIGHT – Why the best sleep position might not be the same for everyone. Continue reading … AMERICAN CULTURE QUIZ – Test yourself on legendary landmarks and fruitful facts. Take the quiz here … POOL PRODIGY – Teen swimmer turns heads after breaking Olympic legend's time. Continue reading … BACKYARD PEST – Seven-foot alligator is dragged out of family's backyard pool. See video … LAWRENCE JONES – Courts are defending the very people who want to cause Americans harm. See video … ADAM CAROLLA – Democrats wonder how they can fool people into voting for them. See video … Tune in to the FOX NEWS RUNDOWN PODCAST for today's in-depth reporting on the news that impacts you. Check it out ... What's it looking like in your neighborhood? Continue reading… Thank you for making us your first choice in the morning! We'll see you in your inbox first thing Friday.

Yahoo
18 minutes ago
- Yahoo
Lands' End: Fiscal Q1 Earnings Snapshot
DODGEVILLE, Wis. (AP) — DODGEVILLE, Wis. (AP) — Lands' End Inc. (LE) on Thursday reported a loss of $8.3 million in its fiscal first quarter. On a per-share basis, the Dodgeville, Wisconsin-based company said it had a loss of 27 cents. Losses, adjusted for one-time gains and costs, were 18 cents per share. The clothing maker posted revenue of $261.2 million in the period. Lands' End expects full-year earnings in the range of 48 cents to 86 cents per share, with revenue in the range of $1.33 billion to $1.45 billion. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on LE at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data